Information  X 
Enter a valid email address

Schroder UK PublicPT (SUPP)

  Print      Mail a friend

Friday 09 April, 2021

Schroder UK PublicPT

Sanofi completes Kymab acquisition

RNS Number : 9548U
Schroder UK Public Private Tst plc
09 April 2021

Schroder UK Public Private Trust plc (the "Company")

Sanofi completes Kymab acquisition

The Company (LSE: SUPP) is pleased to announce the completion of the sale of its shares in Kymab Group Ltd. ("Kymab") to Sanofi. The Company will receive initial proceeds of approximately US$82 million. Furthermore, the Company has the potential for additional contingent payments of up to US$33 million subject to a deferred purchase price release and Kymab achieving certain development and regulatory milestones.

For further information on the completed transaction, investors can refer to the announcement made by the Company on 11th January 2021.

The Company's holding in Kymab has been revalued to £70m reflecting the terms of the agreed sale generating a fair value gain of £52m when compared with the holding value of £18m as at 30 September 2020. The Company intends to publish a full portfolio analysis at the time of the Company's Annual Report for the year ended 31 December 2020 alongside the audited NAV as at 31 December 2020, which is expected to be announced later this month.

The Company intends to use the proceeds to pay down its loan balance, support some of its portfolio companies with follow-on capital and to make new investments into both public and private companies.


Schroder Investment Management Limited

Estelle Bibby (Press)

0207 658 3431


Gareth Faith (Company Secretary)

0207 658 5264



This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

a d v e r t i s e m e n t